Search

Axsome Therapeutics Inc

Затворен

СекторЗдравеопазване

144.04 -6.97

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

143.3

Максимум

154.83

Ключови измерители

By Trading Economics

Приходи

13M

-51M

Продажби

27M

218M

EPS

-0.99

Марж на печалбата

-23.498

Служители

1,346

EBITDA

14M

-47M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+82.89% upside

Дивиденти

By Acuity

Следващи печалби

2.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-2.7B

8.2B

Предишно отваряне

151.01

Предишно затваряне

144.04

Axsome Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.10.2026 г., 20:13 ч. UTC

Axsome Therapeutics Inc shares are trading modestly lower in after-market hours, continuing a notably weak performance below its 20-day moving average.

21.10.2026 г., 23:11 ч. UTC

Axsome Therapeutics Inc is trading higher in after-market hours, rebounding from a brief dip earlier in the session and reaching its highest point of the day.

20.10.2026 г., 23:51 ч. UTC

Axsome Therapeutics Inc shares advanced sharply in after-market trading, rising from a low shortly after the market closed to a session high.

19.10.2026 г., 23:56 ч. UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours, having pulled back from an initial gain shortly after the market closed.

16.10.2026 г., 20:07 ч. UTC

Axsome Therapeutics Inc shares are declining, consistent with broader market weakness, reaching their lowest point since Thursday's close amid a subdued trading environment.

15.10.2026 г., 20:07 ч. UTC

Axsome Therapeutics Inc shares are declining, following volatility earlier in the session, and remain significantly below their 20-day moving average.

14.10.2026 г., 21:01 ч. UTC

Axsome Therapeutics Inc shares are moving lower in after-market trading amid a broader market decline following increased inflation concerns and potential Fed interest rate hikes.

13.10.2026 г., 20:01 ч. UTC

Axsome Therapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes, contrasting with the upward momentum observed since Monday's close.

12.10.2026 г., 23:41 ч. UTC

Axsome Therapeutics Inc shares advanced in after-market trading, showing gains after an initial dip, despite a broader decline over the past month.

9.10.2026 г., 19:35 ч. UTC

Axsome Therapeutics Inc shares fell sharply during the current market session, reflecting a broader trend of lower daily closes over the past month.

8.10.2026 г., 23:01 ч. UTC

Axsome Therapeutics Inc shares are modestly lower in after-market trading, continuing a downward trend since Thursday's close and remaining below its 20-day moving average.

7.10.2026 г., 20:08 ч. UTC

News

Axsome Therapeutics Inc shares fell as the company announced its third-quarter financial results will be released on November 2, 2026, before market open.

6.10.2026 г., 22:35 ч. UTC

Axsome Therapeutics Inc's shares are higher in after-market hours, despite a recent decline and nine consecutive sessions finishing lower.

5.10.2026 г., 19:35 ч. UTC

Axsome Therapeutics Inc shares fell, continuing a downward trend with seven consecutive sessions of lower closes since the market opened.

2.10.2026 г., 20:12 ч. UTC

Axsome Therapeutics Inc is trading modestly lower in after-market hours, continuing a trend with six consecutive sessions finishing lower.

1.10.2026 г., 20:07 ч. UTC

Axsome Therapeutics Inc shares fell sharply, closing lower than Wednesday and remaining significantly below the 20-day moving average.

30.09.2026 г., 21:01 ч. UTC

Axsome Therapeutics Inc's shares rose in after-market trading, supported by positive economic indicators, including stronger GDP growth and robust personal spending.

29.09.2026 г., 20:01 ч. UTC

News

Shares of Axsome Therapeutics fell as Deutsche Bank maintained its Buy rating but lowered the price target to $267 amid reevaluated market conditions.

28.09.2026 г., 20:07 ч. UTC

News

Axsome Therapeutics Inc shares fell amid a broader market downturn, despite presenting new Alzheimer’s agitation survey data at Psych Congress 2026.

25.09.2026 г., 20:07 ч. UTC

News

Axsome Therapeutics shares fell after Morgan Stanley cut its price target to $247 from $251, contributing to a decline near the lower end of its one-month range.

24.09.2026 г., 20:07 ч. UTC

Axsome Therapeutics Inc's shares advanced, recovering from four consecutive sessions of losses, though they remain below their 20-day moving average.

23.09.2026 г., 23:35 ч. UTC

Axsome Therapeutics Inc is trading modestly higher in after-market hours following unusual activity, though it remains significantly below its 20-day moving average.

22.09.2026 г., 19:45 ч. UTC

Axsome Therapeutics Inc shares fell sharply, trading below their 20-day moving average, marking three consecutive sessions of declines amid a weaker market trend.

21.09.2026 г., 20:12 ч. UTC

Axsome Therapeutics Inc is trading modestly lower in after-market hours, remaining near the lower end of its one-month trading range and below its 20-day moving average.

18.09.2026 г., 19:46 ч. UTC

Axsome Therapeutics Inc shares fell after reaching an early high, remaining below Thursday's close and stabilizing around the middle of its one-month trading range.

16.09.2026 г., 20:10 ч. UTC

Macro Event

Axsome Therapeutics Inc is advancing amid broader market reactions to the Federal Reserve's 25 basis point interest rate hike, consolidating gains above its 20-day moving average.

15.09.2026 г., 21:01 ч. UTC

Axsome Therapeutics Inc shares are lower in after-market hours, showing unusual volatility and trading below its 20-day moving average. No specific news was identified.

14.09.2026 г., 20:07 ч. UTC

Social Media

Axsome Therapeutics shares are lower today, continuing a decline since Friday. Recent prescription data and a price target of $316 from Mizuho have not supported the stock.

12.09.2026 г., 00:01 ч. UTC

Social Media

Axsome Therapeutics shares rise in after-market trading, supported by Mizuho's $316 price target and positive prescription data for Auvelity.

11.09.2026 г., 20:01 ч. UTC

News
Social Media

Axsome Therapeutics shares rise following positive analyst commentary on Auvelity's launch and strong prescription growth, with unusually high trading volume today.

Сравнение с други в отрасъла

Ценова промяна

Axsome Therapeutics Inc Прогноза

Ценова цел

By TipRanks

82.89% нагоре

12-месечна прогноза

Среден 285.875 USD  82.89%

Висок 380 USD

Нисък 247 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Axsome Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

16

Купи

1

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat